| 118.1 0.93 (0.79%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 142.74 | 1-year : | 166.72 |
| Resists | First : | 122.2 | Second : | 142.74 |
| Pivot price | 111.75  |
|||
| Supports | First : | 99.91 |
Second : | 86.13 |
| MAs | MA(5) : | 114.48 |
MA(20) : | 107.22 |
| MA(100) : | 73.18 |
MA(250) : | 66.52 |
|
| MACD | MACD : | 6.7 |
Signal : | 6.6 |
| %K %D | K(14,3) : | 82.3 |
D(3) : | 75.4 |
| RSI | RSI(14): 67.7 |
|||
| 52-week | High : | 122.2 | Low : | 28.65 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CORT ] has closed below upper band by 22.8%. Bollinger Bands are 36.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 120.09 - 120.56 | 120.56 - 121.02 |
| Low: | 115.38 - 115.94 | 115.94 - 116.49 |
| Close: | 117.21 - 118.06 | 118.06 - 118.9 |
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Tue, 18 Aug 2026
Corcept Therapeutics (NASDAQ:CORT) Director James Wilson Sells 10,000 Shares of Stock - marketbeat.com
Tue, 18 Aug 2026
Corcept Therapeutics (NASDAQ:CORT) Insider Sells 3,664 Shares of Stock - marketbeat.com
Tue, 18 Aug 2026
Corcept (NASDAQ: CORT) exec sells 10,000 shares at $116 - Stock Titan
Tue, 18 Aug 2026
Corcept (NASDAQ: CORT) director sells 10,000 shares under 10b5-1 plan - Stock Titan
Tue, 18 Aug 2026
Truist Adjusts Price Target on Corcept Therapeutics to $164 From $50, Maintains Buy Rating - marketscreener.com
Mon, 17 Aug 2026
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 108 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 11.4 (%) |
| Held by Institutions | 76.4 (%) |
| Shares Short | 9,440 (K) |
| Shares Short P.Month | 8,570 (K) |
| EPS | 0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.53 |
| Profit Margin | 6.6 % |
| Operating Margin | 16.1 % |
| Return on Assets (ttm) | 0.4 % |
| Return on Equity (ttm) | 8.2 % |
| Qtrly Rev. Growth | 31.7 % |
| Gross Profit (p.s.) | 7.55 |
| Sales Per Share | 7.68 |
| EBITDA (p.s.) | 0.07 |
| Qtrly Earnings Growth | 24.1 % |
| Operating Cash Flow | 110 (M) |
| Levered Free Cash Flow | 77 (M) |
| PE Ratio | 262.44 |
| PEG Ratio | 0.8 |
| Price to Book value | 18.05 |
| Price to Sales | 15.36 |
| Price to Cash Flow | 116.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|